search
Back to results

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Primary Purpose

Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer

Status
Not yet recruiting
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
VLS-1488
Sponsored by
Volastra Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Solid Tumor focused on measuring KIF18A Inhibitor

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria: All Parts: Age ≥ 18 years, ECOG Performance Status ≤ 1, at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1, able to take oral medication without alteration Dose Escalation: No available therapeutic options to provide clinically meaningful benefits in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non -Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction, Bladder (transitional cell), Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), Ovarian Carcinosarcoma, CN-high Endometrial/Uterine Dose Expansion: Must have been previously treated with several lines of standard of care treatment specified in the protocol in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), CN-high Endometrial/Uterine Key Exclusion Criteria: MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype Previously received KIF18A inhibitor Current CNS metastases or leptomeningeal disease Cardiac parameters: MI or stroke ≤ 1 year, unstable angina/PE/DVT/CABG ≤ 6 months, NYHA Class ≥ II, LVEF < 50% Inability to comply with concomitant medication restrictions with respect to strong inhibitors and inducers of CYP3A, and clinical inhibitors of MDR1 (P-gp) and BCRP Any clinically significant ascites or pleural effusions at time of enrollment, or any therapeutic paracentesis or thoracentesis within 28 days of planned first dose of study drug Bowel obstruction or GI perforation within 6 months of planned first dose of study drug

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Experimental

    Experimental

    Experimental

    Arm Label

    Dose Escalation: Dose Escalation Cohorts

    Dose Escalation: Backfill Cohorts

    Dose Expansion: Exploration Cohorts

    Dose Expansion: Development Cohorts

    Arm Description

    Subjects will be enrolled at various doses and/or schedules of VLS-1488. These Dose Escalation Cohorts will be utilized to identify the MTD and to select dose levels for Dose Expansion.

    Additional subjects may be enrolled at any dose level that does not meet de-escalation or elimination rules per the BOIN design. These Backfill Cohorts will be utilized to build additional data to support selection of doses and/or tumor types for further study in Dose Expansion.

    Subjects with a selected single tumor type will be randomized 1:1 into Exploration Cohorts at two or more dose levels of interest. A subset of subjects will have additional assessments to examine the potential for VLS-1488 to interact with other drugs and the effect of food on VLS-1488 absorption.

    Subjects with other tumor types will be enrolled at a single dose level of interest. These Development Cohorts will be utilized to examine the preliminary efficacy of VLS-1488 in various tumor types.

    Outcomes

    Primary Outcome Measures

    Dose Escalation: Incidence of Dose Limiting Toxicities (DLTs) in DLT-evaluable subjects
    Dose Escalation: Determination of the MTD of VLS-1488
    Dose Escalation: Frequency of Serious Adverse Events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0
    Dose Escalation: Frequency of Treatment-related Adverse Events (AEs) graded per NCI-CTCAE version 5.0
    Dose Escalation: Frequency of Treatment-Emergent AEs (TEAEs) graded per NCI-CTCAE version 5.0
    Dose Escalation: Frequency of Dose Interruptions and Permanent Treatment Discontinuations
    Dose Expansion: Frequency of Trigger Events (TEs)
    Dose Expansion: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Secondary Outcome Measures

    Dose Escalation: ORR as assessed by RECIST version 1.1
    Dose Expansion: Frequency of SAEs graded according to NCI-CTCAE version 5.0
    Dose Expansion: Frequency of Treatment-related AEs graded according to NCI-CTCAE version 5.0
    Dose Expansion: Frequency of TEAEs graded according to NCI-CTCAE version 5.0
    Dose Expansion: Frequency of Dose Interruptions and Permanent Treatment Discontinuations
    Dose Expansion: Area Under the Plasma Concentration-Time Curve (AUC) of Midazolam and its metabolite 1'-hydroxymidazolam
    Dose Expansion: Maximum Plasma Concentration (Cmax) of Midazolam and its metabolite 1'-hydroxymidazolam
    Dose Expansion: Evaluation of CA-125 response by Gynecologic Cancer InterGroup (GCIG) criteria (High Grade Serous Ovarian Cancer only)
    Dose Escalation & Dose Expansion: Duration of Response (DOR) as assessed by RECIST version 1.1
    Dose Escalation & Dose Expansion: Disease Control Rate (DCR) as assessed by RECIST version 1.1
    Dose Escalation & Dose Expansion: Progression Free Survival (PFS) as assessed by RECIST version 1.1
    Dose Escalation & Dose Expansion: Cmax of VLS-1488
    Dose Escalation & Dose Expansion: AUC of VLS-1488
    Dose Escalation & Dose Expansion: Trough Concentration (Ctrough) of VLS-1488
    Dose Escalation & Dose Expansion: Time to Maximum Plasma Concentration (Tmax) of VLS-1488
    Dose Escalation & Dose Expansion: Ratio of Total Cholesterol to 4β-hydroxycholesterol in plasma
    Dose Escalation & Dose Expansion: Increase in the number of Phospho-Histone 3 positive tumor cells
    Dose Escalation & Dose Expansion: Frequency of Micronucleated Reticulocytes in blood
    Dose Escalation & Dose Expansion: Increase in Micronuclei in Circulating Tumor Cells

    Full Information

    First Posted
    May 31, 2023
    Last Updated
    July 25, 2023
    Sponsor
    Volastra Therapeutics, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05902988
    Brief Title
    A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
    Official Title
    A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 2023 (Anticipated)
    Primary Completion Date
    December 2025 (Anticipated)
    Study Completion Date
    June 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Volastra Therapeutics, Inc.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
    Detailed Description
    This a first-in-human phase I/II study designed to assess the safety, tolerability and preliminary efficacy of VLS-1488 monotherapy and consists of two parts: Dose Escalation and Dose Expansion. Dose Escalation will examine the safety and tolerability of VLS-1488 in different solid tumor types at various dose levels through a series of Dose Escalation and Backfill Cohorts to identify the Maximum Tolerated Dose (MTD) and to select dose levels for Dose Expansion. The criteria for dose (de-)escalation will be based on a Bayesian Optimal Interval (BOIN) design. Dose Expansion will examine the safety, tolerability, Drug Drug Interaction (DDI) risk, Food Effect (FE) and preliminary efficacy of VLS-1488 in different tumor types and/or dose levels of interest through various expansion cohorts. VLS-1488 will be given orally in 28-day cycles. Dosing will be continued until disease progression, unacceptable toxicity, withdrawal of consent, or other stopping criteria are met.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Transitional Cell Carcinoma of Bladder, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
    Keywords
    KIF18A Inhibitor

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1, Phase 2
    Interventional Study Model
    Sequential Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    120 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Dose Escalation: Dose Escalation Cohorts
    Arm Type
    Experimental
    Arm Description
    Subjects will be enrolled at various doses and/or schedules of VLS-1488. These Dose Escalation Cohorts will be utilized to identify the MTD and to select dose levels for Dose Expansion.
    Arm Title
    Dose Escalation: Backfill Cohorts
    Arm Type
    Experimental
    Arm Description
    Additional subjects may be enrolled at any dose level that does not meet de-escalation or elimination rules per the BOIN design. These Backfill Cohorts will be utilized to build additional data to support selection of doses and/or tumor types for further study in Dose Expansion.
    Arm Title
    Dose Expansion: Exploration Cohorts
    Arm Type
    Experimental
    Arm Description
    Subjects with a selected single tumor type will be randomized 1:1 into Exploration Cohorts at two or more dose levels of interest. A subset of subjects will have additional assessments to examine the potential for VLS-1488 to interact with other drugs and the effect of food on VLS-1488 absorption.
    Arm Title
    Dose Expansion: Development Cohorts
    Arm Type
    Experimental
    Arm Description
    Subjects with other tumor types will be enrolled at a single dose level of interest. These Development Cohorts will be utilized to examine the preliminary efficacy of VLS-1488 in various tumor types.
    Intervention Type
    Drug
    Intervention Name(s)
    VLS-1488
    Intervention Description
    VLS-1488 tablets will be given orally.
    Primary Outcome Measure Information:
    Title
    Dose Escalation: Incidence of Dose Limiting Toxicities (DLTs) in DLT-evaluable subjects
    Time Frame
    Up to 12 months
    Title
    Dose Escalation: Determination of the MTD of VLS-1488
    Time Frame
    Up to 12 months
    Title
    Dose Escalation: Frequency of Serious Adverse Events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0
    Time Frame
    Up to 12 months
    Title
    Dose Escalation: Frequency of Treatment-related Adverse Events (AEs) graded per NCI-CTCAE version 5.0
    Time Frame
    Up to 12 months
    Title
    Dose Escalation: Frequency of Treatment-Emergent AEs (TEAEs) graded per NCI-CTCAE version 5.0
    Time Frame
    Up to 12 months
    Title
    Dose Escalation: Frequency of Dose Interruptions and Permanent Treatment Discontinuations
    Time Frame
    Up to 12 months
    Title
    Dose Expansion: Frequency of Trigger Events (TEs)
    Time Frame
    Up to 18 months
    Title
    Dose Expansion: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
    Time Frame
    Up to 18 months
    Secondary Outcome Measure Information:
    Title
    Dose Escalation: ORR as assessed by RECIST version 1.1
    Time Frame
    Up to 12 months
    Title
    Dose Expansion: Frequency of SAEs graded according to NCI-CTCAE version 5.0
    Time Frame
    Up to 18 months
    Title
    Dose Expansion: Frequency of Treatment-related AEs graded according to NCI-CTCAE version 5.0
    Time Frame
    Up to 18 months
    Title
    Dose Expansion: Frequency of TEAEs graded according to NCI-CTCAE version 5.0
    Time Frame
    Up to 18 months
    Title
    Dose Expansion: Frequency of Dose Interruptions and Permanent Treatment Discontinuations
    Time Frame
    Up to 18 months
    Title
    Dose Expansion: Area Under the Plasma Concentration-Time Curve (AUC) of Midazolam and its metabolite 1'-hydroxymidazolam
    Time Frame
    Up to 18 months
    Title
    Dose Expansion: Maximum Plasma Concentration (Cmax) of Midazolam and its metabolite 1'-hydroxymidazolam
    Time Frame
    Up to 18 months
    Title
    Dose Expansion: Evaluation of CA-125 response by Gynecologic Cancer InterGroup (GCIG) criteria (High Grade Serous Ovarian Cancer only)
    Time Frame
    Up to 18 months
    Title
    Dose Escalation & Dose Expansion: Duration of Response (DOR) as assessed by RECIST version 1.1
    Time Frame
    Up to 32 months
    Title
    Dose Escalation & Dose Expansion: Disease Control Rate (DCR) as assessed by RECIST version 1.1
    Time Frame
    Up to 32 months
    Title
    Dose Escalation & Dose Expansion: Progression Free Survival (PFS) as assessed by RECIST version 1.1
    Time Frame
    Up to 32 months
    Title
    Dose Escalation & Dose Expansion: Cmax of VLS-1488
    Time Frame
    Up to 32 months
    Title
    Dose Escalation & Dose Expansion: AUC of VLS-1488
    Time Frame
    Up to 32 months
    Title
    Dose Escalation & Dose Expansion: Trough Concentration (Ctrough) of VLS-1488
    Time Frame
    Up to 32 months
    Title
    Dose Escalation & Dose Expansion: Time to Maximum Plasma Concentration (Tmax) of VLS-1488
    Time Frame
    Up to 32 months
    Title
    Dose Escalation & Dose Expansion: Ratio of Total Cholesterol to 4β-hydroxycholesterol in plasma
    Time Frame
    Up to 32 months
    Title
    Dose Escalation & Dose Expansion: Increase in the number of Phospho-Histone 3 positive tumor cells
    Time Frame
    Up to 32 months
    Title
    Dose Escalation & Dose Expansion: Frequency of Micronucleated Reticulocytes in blood
    Time Frame
    Up to 32 months
    Title
    Dose Escalation & Dose Expansion: Increase in Micronuclei in Circulating Tumor Cells
    Time Frame
    Up to 32 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Key Inclusion Criteria: All Parts: Age ≥ 18 years, ECOG Performance Status ≤ 1, at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1, able to take oral medication without alteration Dose Escalation: No available therapeutic options to provide clinically meaningful benefits in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non -Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction, Bladder (transitional cell), Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), Ovarian Carcinosarcoma, CN-high Endometrial/Uterine Dose Expansion: Must have been previously treated with several lines of standard of care treatment specified in the protocol in the following tumor types: High Grade Serous Ovarian Cancer, Squamous Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma (not EBV+), Colorectal, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinomas (not nasopharynx, sinonasal or lip), CN-high Endometrial/Uterine Key Exclusion Criteria: MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype Previously received KIF18A inhibitor Current CNS metastases or leptomeningeal disease Cardiac parameters: MI or stroke ≤ 1 year, unstable angina/PE/DVT/CABG ≤ 6 months, NYHA Class ≥ II, LVEF < 50% Inability to comply with concomitant medication restrictions with respect to strong inhibitors and inducers of CYP3A, and clinical inhibitors of MDR1 (P-gp) and BCRP Any clinically significant ascites or pleural effusions at time of enrollment, or any therapeutic paracentesis or thoracentesis within 28 days of planned first dose of study drug Bowel obstruction or GI perforation within 6 months of planned first dose of study drug
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Volastra Therapeutics, Inc.
    Phone
    (646) 344-1248
    Email
    clinicaltrials@volastratx.com

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

    We'll reach out to this number within 24 hrs